C. R. Bard, Inc. (NYSE:BCR) announced today that experts will present the 6-month LEVANT 2 trial results on its Lutonix drug coated balloon (DCB) and provide an update on the ongoing Lutonix Below the Knee (BTK) Clinical Trial at the Leipzig Interventional Course (LINC) in Leipzig, Germany.
Help employers find you! Check out all the jobs and post your resume.
